Dr. Daniel A. King, M.D., PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Wayne State University School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 285800 -
Internal Medicine Physician
NY license 285800 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Long Island Jewish Medical Center New Hyde PArk, NY
Medical groups
- North Shore Health System Medical Faculty Group Practice Inc (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 876
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 293 | 83 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 44 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 36 | 36 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 13 |
| Creon (lipase/protease/amylase) Other prescribers in New Hyde PArk, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $12,188 in total to this clinician.
| Partner Therapeutics, Inc. | $4,295 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $3,645 |
| Histosonics, Inc. | $2,150 |
| AstraZeneca UK Limited | $2,010 |
| AstraZeneca Pharmaceuticals LP | $88.09 |
| Compensation for services other than consulting (speaking, faculty) | $6,230 |
|---|---|
| Consulting Fee | $4,010 |
| Travel and Lodging | $1,549 |
| Food and Beverage | $399 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Partner Therapeutics, Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) Bizengri · Hematology/Oncology | $3,500 |
| Ipsen Biopharmaceuticals, Inc May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde · Oncology | $2,730 |
| AstraZeneca UK Limited Nov 6, 2025 | Consulting Fee | $2,010 |
| Histosonics, Inc. Oct 23, 2025 | Consulting Fee | $2,000 |
| Ipsen Biopharmaceuticals, Inc May 30, 2025 | Travel and Lodging Onivyde · Oncology · travel to Chicago, IL · in-kind | $754 |
| Partner Therapeutics, Inc. Sep 13, 2025 | Travel and Lodging LEUKINE · Hematology/Oncology · travel to Nashville, TN · in-kind | $479 |
| Partner Therapeutics, Inc. Oct 1, 2025 | Travel and Lodging BIZENGRI · Hematology/Oncology · travel to Nashville, TN | $292 |
| Partner Therapeutics, Inc. Oct 1, 2025 | Travel and Lodging BIZENGRI · Hematology/Oncology · travel to Nashville, TN | $24.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $436,569 in research payments for these studies, mostly to the institutions running them.
- Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC
Genentech, Inc. - A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.